Mosley Wealth Management Makes New $529,000 Investment in Gilead Sciences, Inc. $GILD

12 Jun 2026, 15:54 by Danessa Lincoln · The Markets Daily

Mosley Wealth Management acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 4,473 shares of the biopharmaceutical company’s stock, valued at approximately $529,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Banco BTG Pactual S.A. bought a new position in Gilead Sciences in the 4th quarter valued at $726,000. Great Valley Advisor Group Inc. grew its position in Gilead Sciences by 5.5% in the 4th quarter. Great Valley Advisor Group Inc. now owns 5,170 shares of the biopharmaceutical company’s stock valued at $635,000 after acquiring an additional 271 shares during the last quarter. Kovack Advisors Inc. grew its position in Gilead Sciences by 572.9% in the 4th quarter. Kovack Advisors Inc. now owns 25,422 shares of the biopharmaceutical company’s stock valued at $3,120,000 after acquiring an additional 21,644 shares during the last quarter. ICICI Prudential Asset Management Co Ltd grew its position in Gilead Sciences by 4.5% in the 4th quarter. ICICI Prudential Asset Management Co Ltd now owns 19,911 shares of the biopharmaceutical company’s stock valued at $2,444,000 after acquiring an additional 856 shares during the last quarter. Finally, Hudock Inc. bought a new position in shares of Gilead Sciences during the 4th quarter worth $217,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: Bernstein initiated/maintained a Buy view on Gilead, adding to the bullish analyst sentiment around the stock. Gilead Sciences (GILD) Gets a Buy from Bernstein
Positive Sentiment: Gilead and Merck reported positive topline Phase 3 results for their once-weekly oral HIV regimen (islatravir + lenacapavir), which strengthens the company’s growth story and HIV franchise outlook. Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?
Positive Sentiment: Gilead’s HIV business continues to get attention for momentum from Biktarvy, Descovy, and Yeztugo, with late-stage pipeline progress supporting the long-term earnings outlook. Can Gilead Sciences HIV Franchise Drive Long-Term Growth?
Positive Sentiment: Recent Phase 3 IDEAL study results for Livdelzi in primary biliary cholangitis also reinforced confidence in Gilead’s pipeline development. Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development
Neutral Sentiment: Gilead was cited in broader articles about pharma/biotech M&A and healthcare investing, which may keep the stock on traders’ radar but does not directly change fundamentals. Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
Neutral Sentiment: Unusually heavy call-option activity suggests traders are positioning for more upside, though it is not a fundamental development.
Neutral Sentiment: Gilead Foundation’s ~$3 million HIV/AIDS education commitment is positive for brand and ESG perception, but the financial impact is likely limited. National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

Gilead Sciences Trading Up 3.6%

Shares of NASDAQ GILD opened at $125.87 on Friday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The stock has a market capitalization of $156.28 billion, a P/E ratio of 17.15 and a beta of 0.31. Gilead Sciences, Inc. has a 1-year low of $104.46 and a 1-year high of $157.29. The business has a fifty day moving average price of $133.46 and a 200 day moving average price of $134.34.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio is 44.69%.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the completion of the sale, the chief executive officer directly owned 617,567 shares in the company, valued at $81,185,357.82. This represents a 2.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the sale, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 68,000 shares of company stock worth $9,047,570 in the last three months. 0.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on GILD. Mizuho increased their price target on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Truist Financial reissued a “buy” rating and set a $157.00 price target (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Royal Bank Of Canada reissued a “sector perform” rating on shares of Gilead Sciences in a research report on Monday. Wolfe Research increased their price target on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Finally, Needham & Company LLC reissued a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a research report on Monday, February 23rd. Twenty-five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $156.93.

View Our Latest Stock Analysis on GILD

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.